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BACKGROUND & AIMS:Abbreviations used in this pap
terval at 95%; CRP, C-reactive
ratio; TNF-a, tumor necrosis
ulcerative colitis endoscopic in
88It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard
therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large








97We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP
refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the
GETAID cohort). Patients received at least 1 injection of anti-TNF (infliximab, adalimumab, goli-
mumab) from October 2006 through February 2017. Clinical response was defined as significant
improvement in UC-related symptoms, and remission as complete disappearance of UC-related
symptoms, each determined by treating physicians. We collected demographic, clinical, and treat-
ment data. The median duration of follow-up was 24 months (interquartile range, 13–51 months).





104Overall, 80patients (77%)hadaclinical responsetoanti-TNFtherapyand52patients (50%)achieved
clinical remission. Extra-intestinal manifestations (odds ratio OR, 0.24; 95% CI, 0.08–0.7), ongoing
treatment with topical steroids (OR, 0.14; 95% CI, 0.03–0.73), and ongoing treatment with topical
5-aminosalycilates (OR, 0.21; 95% CI, 0.07–0.62) were significantly associated with the absence of
clinical remission. Sixty percent (38/63) of the patients who had endoscopic assessment during
followuphadmucosal healing. Among theoverall population (n[104), the cumulative probabilities
of sustained clinical remission were 87.6% – 3.4% at 1 year and 74.7% – 4.8% at 2 years.105
106CONCLUSIONS:
107
108In a retrospective study of 104 patients with refractory UP, anti-TNF therapy induced clinical
remission in 50% and mucosal healing in 60%. About two thirds of the patients were still
receiving anti-TNF therapy at 2 years.109110Keywords: Inflammatory Bowel Disease; Second-Line Treatment; Immune Suppression; Trial; Proctitis.
111
112er: AZA, azathioprine; CI, confidence in-
protein; IQR, interquartile range; OR, odds
factor-a; UC, ulcerative colitis; UCEIS,
dex of severity; UP, ulcerative proctitis.
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What You Need to Know
Background
Management of refractory ulcerative proctitis is
challenging as patients with ulcerative colitis limited
to the rectum are systematically excluded from ran-
domized clinical trials investigating efficacy of bi-
ologics. We investigated the effectiveness of tumor
necrosis factor (TNF) antagonists in a large cohort of
patients with refractory ulcerative proctitis.
Findings
In a retrospective study of 104 patients with re-
fractory ulcerative proctitis, anti-TNF therapy
induced clinical remission in 50% and mucosal
healing in 60%. About two thirds of the patients were
still receiving anti-TNF therapy at 2 years.
Implications for patient care
Anti-TNF agents might be a good therapeutic option
for patients with ulcerative proctitis.



















































































































231Ulcerative colitis (UC) is a chronic inflammatorybowel disease characterized by intestinal inflam-
mation limited to the colonic mucosa.1 In population-
based studies, 25%–55% of patients had ulcerative
proctitis (UP) at diagnosis.2 UP defined as a disease
limited to the rectum is classified as E1 according to
the Montreal classification.3 Although it is generally
assumed that UP represents the benign end of the spec-
trum of UC, it is responsible for many distressing symp-
toms including increased stool frequency, tenesmus,
urgency, and bleeding, and clearly alters patients’ quality
of life.2 Despite the significant benefits of aminosalicy-
lates and corticosteroids, some patients with UP fail to
improve and require additional medical therapy.
Medical management of patients with UP refractory
to standard therapies is challenging because there is
little evidence-based data regarding drug efficacy in this
clinical situation.4 Several medications have been tested
to treat refractory UP.5 In a randomized controlled trial,
azathioprine (AZA) was more effective than oral mesal-
amine to achieve steroid-free clinical and endoscopic
remission.6 Cyclosporin enemas and oral methotrexate
have not proven to be significantly effective in inducing
and maintaining long-term clinical response and
remission.6–8 A recent randomized, placebo-controlled,
trial demonstrated that tacrolimus rectal ointment was
more effective than placebo for the induction of clinical
remission and mucosal healing in patients with UP.9
Appendectomy has also been proposed as a treatment
for patients with refractory UP.10 Overall, these results
remain difficult to interpret because of small sample size
and the lack of well-designed published studies sup-
porting their efficacy for refractory UP.
Furthermore, patients with UC limited to the rectum
are systematically excluded from randomized clinical
trials on biologics. Topical administration of infliximab
was found to be effective in 1 patient with chronic re-
fractory UP.11 Only 1 French small retrospective obser-
vational study has investigated the efficacy of infliximab
in patients with refractory UP.12 Regarding short-term
outcome, 69% (9/13) patients presented a complete
response to infliximab. To date, there are no data
regarding efficacy of adalimumab, golimumab, or other
biologics in patients with refractory UP.
The aim of this study was therefore to evaluate the
effectiveness of anti–tumor necrosis factor (TNF) ther-
apy in a large nationwide retrospective cohort study
from the Groupe d’Etude Thérapeutique des Affections
Inflammatoires du tube Digestif (GETAID).
Methods
Selection of Patients
A retrospective observational study was performed in
15 French and 1 Belgium referral center affiliated withFLA 5.6.0 DTD  YJCGH56568_proofGETAID. All consecutive patients with a diagnosis of UC
based on clinical, biologic, and morphologic criteria ac-
cording to European guidelines, and with an active UP
according to treating physician (maximal extension of
macroscopic endoscopic lesions <20 cm from the anal
verge) refractory to conventional therapies (topical and
oral mesalamine, topical and systemic corticosteroids and/
or thiopurines) who were treated with at least 1 injection
of a monoclonal anti-TNF-a antibody (infliximab, adali-
mumab, golimumab) from October 2006 to February 2017
were included in the study. The study protocol was
approved by the Montpellier University institutional re-
view board. All authors had access to the study data, and
reviewed and approved the final manuscript.Data Collection
The date of inclusion corresponded to the first admin-
istration of anti-TNF therapy. Patient files were retrospec-
tively reviewed and demographic, biologic, and endoscopic
data were obtained from themedical records. The following
characteristics were anonymously recorded for each
included patient: gender; age at inclusion; date of diagnosis;
duration of disease; smoking status; presence of extra-
intestinal manifestations; prior exposure to UC treatment
including local and systemic steroids, local and oral mesal-
amine, and conventional immunosuppressants (thio-
purines, methotrexate, and cyclosporin); UP clinical activity
before the start of anti-TNF based onMayo clinical subscore
(from 0 to 9) and endoscopic findings (Mayo endoscopic
subscore andUlcerativeColitis Endoscopic Index of Severity
[UCEIS]) when available; main indication for introducing
anti-TNF; type of anti-TNF (infliximab, adalimumab, or 11 July 2019  9:13 pm  ce CJ
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299golimumab); anti-TNF induction and maintenance doses;
type of response (no response, partial response, and com-
plete response); concomitant treatment with thiopurines;
other ongoing drugs at commencement of anti-TNF; dura-
tion of anti-TNF treatment; optimization of the treatment; C-
reactive protein levels (CRP); and endoscopic findings at
inclusion and during follow-up. All data were encoded in an
Excel electronic database that was anonymized with attri-









































The primary objective was to assess the primary
clinical response of UP to anti-TNF treatment. Evaluation
of the global clinical response to anti-TNF was based on
the judgement of the referring physician and was graded
as follows: no response, clinical response, and clinical
remission. Clinical response was defined as significant
improvement in UC-related symptoms as judged by the
treating physician. Remission was defined as the com-
plete disappearance of UC-related symptoms as judged
by the treating physician. Clinical outcomes were
collected by local investigators from retrospective notes
in each patient chart. Definitions of primary outcomes
were clearly defined in study protocol and explained to
each local investigator before data collection.
Secondary outcomes were: (1) clinical response and
remission during the induction phase (first 3 months),
(2) changes in the Mayo clinical subscore (retrospec-
tively calculated from physician notes) between anti-TNF
therapy initiation and Week 12, (3) mucosa healing
during follow-up (defined as a Mayo endoscopic sub-
score of 0 or 1) among patients who underwent endo-
scopic assessment, (4) changes in the Mayo endoscopic
subscore or UCEIS index prospectively assessed before
anti-TNF initiation and during the first follow-up colo-
noscopy, (5) coloproctectomy during follow-up, (6) the
identification of predictive factors of anti-TNF efficacy,
(6) the cumulative probability of anti-TNF retention
among primary responders, and (7) the safety of anti-
TNF treatment. The rate of anti-TNF optimization was
also recorded, but was not considered to be a loss of
clinical benefit. To determine safety, all adverse events,
defined as any significant event that occurred from the
date of inclusion to the last follow-up, were recorded in
patients receiving at least 1 injection of any anti-TNF
agents. Severe adverse events were defined as any
adverse event that resulted in hospitalization or exten-
sion of the hospital stay, was fatal or life threatening, or








Descriptive statistics were used to analyze baseline
characteristics. Medians with interquartile ranges (IQR)
or means with standard deviations were calculated for
continuous data, and percentages were computed forFLA 5.6.0 DTD  YJCGH56568_proofdiscrete data. Univariate and multivariate logistic
regression were performed to identify predictive factors
associated to clinical remission with anti-TNF treatment,
expressed as odds ratios (OR) with 95% confidence in-
tervals (CI). Variables with a P < .1 were used for
multivariate analysis. For multivariate analysis adjusted
for sex and age at diagnosis, variables included were
extraintestinal manifestations, the type of anti-TNF
(subcutaneous vs intravenous), concomitant thio-
purines, ongoing treatment with topical mesalamine, and
topical steroids. Proportion of patients with sustained
clinical remission and anti-TNF failure (defined as the
occurrence of anti-TNF withdrawal for loss of response
or intolerance and/or colectomy) over time were
described using Kaplan-Meier survival analysis. A P < .05
was considered to be significant.
Results
Patient Characteristics
Included in the study were 104 patients (51 female
and 53 male) with refractory UP treated with anti-TNF-a
from 16 GETAID centers, with a median follow-up of 24
(IQR, 12.9–51.2) months. The baseline demographic and
clinical characteristics of the patients are presented in
Table 1. Mean age at diagnosis was 34  11.9 years. Anti-
TNF therapy was started after a median follow-up of 46
(IQR, 19.8–110.5) months from the diagnosis of UP.
Fifty percent (52/104) of the patients were treated
with infliximab, 39% (41/104) with adalimumab, and
11% (11/104) with golimumab. Fifty-three (55/104)
percent of patients were concomitantly treated with
topical or oral mesalamine or steroids at the start of anti-
TNF therapy. Anti-TNF was associated with a thiopurine
in 38% (40/104) of the patients. Patients were initially
treated with the recommended dose of anti-TNF for in-
duction. Following initiation of anti-TNF, 47% (49/104)
of patients had an intensification of the anti-TNF agent
after a median duration of follow-up of 6 (IQR, 3–13.6)
months; 17 patients had a dose increase, 24 a shortening
of the injection interval, and 8 both dose increase and
interval shortening.
Short-Term Outcomes
Following a median duration of follow-up of 3
(IQR,1.6–7.0) months between anti-TNF initiation and
clinical evaluation, 77% (80/104) of patients had a pri-
mary clinical response to the anti-TNF agent and 50%
(52/104) achieved clinical remission (Figure 1).
Corticosteroid-free remission was achieved in 45%
(n ¼ 47/104) of the patients. The mean Mayo clinical
subscore before the start of anti-TNF-a was of 5.9  1.9
points (n ¼ 99). At 3 months after anti-TNF start 42%
(33/78) of the patients had a Mayo clinical subscore <2.
In patients with clinical scores available at baseline and 3 11 July 2019  9:13 pm  ce CJ





Mean age at diagnosis, y  SD 34  11.9
Median duration of disease before
anti-TNF, y (IQR,1–3)
46 (19.8–110.5)
Active smokers, n (%) 6 (6)
Extraintestinal manifestations, n (%)
Arthralgia and ankylosing spondylitis 24 (23)
Skin or mucosal lesions 3 (3)
Uveitis 1 (0.9)
UC treatment before anti-TNF, n (%)
Topical mesalamine 100 (96)
Oral mesalamine 99 (95)
Topical corticosteroids 85 (82)





Mean Mayo clinical subscore before
anti-TNF,  SD
5.9  1.9
Mayo endoscopic subscore before
anti-TNF, n (%) (n ¼ 88)
Mayo 1 6 (7)
Mayo 2 45 (51)
Mayo 3 36 (41)
Mean UCEIS endoscopic index before
anti-TNF,  SD
4.9  1.4




Reasons for anti-TNF, n (%)
Steroid-dependency 23 (22)
Failure of corticosteroids 27 (26)
Failure of immunosuppressant drugs 49 (47)
Other reasons 7 (7)
Concomitant therapies, n (%)
Thiopurines 40 (38)
Methotrexate 7 (7)
Topical mesalamine 26 (25)
Oral mesalamine 16 (15)
Topical corticosteroids 15 (14)
Oral corticosteroids 26 (25)
ADA, adalimumab; anti-TNF, anti-tumor necrosis factor alpha monoclonal
antibodies; GOL, golimumab; IFX, infliximab; IQR, interquartile range; SD,
standard deviation; UC, ulcerative colitis; UCEIS, ulcerative colitis endoscopic
index of severity.




















































































































464months after anti-TNF-a start (n ¼ 76), we observed a
significant decrease in the Mayo clinical subscore (5.9 
1.9 vs 2.5  2.6; P < .001) between baseline and Week
12 evaluation and 58% of the patients presented at least
a clinical response defined by a decreased in the Mayo
clinical subscore of 3 or more points with bleeding score
of 0 or 1. Among patients with an available CRP at
baseline and 3 months after anti-TNF treatment initia-
tion (n ¼ 49), there was a significant decrease in the
mean CRP level (11.6  21.4 at inclusion vs 4.7  4.6 atFLA 5.6.0 DTD  YJCGH56568_proofthe end of the anti-TNF induction period; P ¼ .028)
(Supplementary Table 1).
Factors Associated With Short-Term Outcomes
In univariate analysis, extraintestinal manifestations,
ongoing topical steroids at baseline, and ongoing topical
mesalamine at baseline were significantly associated
with the absence of primary clinical remission (Table 2).
Concomitant treatment with thiopurines at baseline was
significantly associated with primary clinical remission
(Table 2). In a multivariate analysis adjusted for sex and
age at diagnosis and including as variables extra-
intestinal manifestations, the type of anti-TNF (subcu-
taneous vs intravenous), concomitant thiopurines,
ongoing treatment with topical mesalamine and topical
steroids, extraintestinal manifestations (OR, 0.24; 95%
CI, 0.08–0.7; P ¼ .009), ongoing topical steroids at
baseline (OR, 0.14; 95% CI, 0.03–0.73; P ¼ .019), and
ongoing topical mesalamine at baseline (OR, 0.21; 95%
CI, 0.07–0.62; P ¼ .007) were independently associated
with the absence of primary clinical remission (Table 2).
Endoscopic Findings
A baseline colonoscopy was available in 82% (85/
104) patients with a median delay before anti-TNF start
of 0.9 (IQR, 0.1–2.16) months. A follow-up colonoscopy
was available in 61% (63/104) of patients after a median
follow-up of 11.7 (IQR, 5.5–17.4) months. Among these
patients, 60% (38/63) had mucosal healing (Mayo
endoscopic subscore of 0 or 1) (Figure 1). Among these
patients, there was a significant decrease in the Mayo
endoscopic subscore (2.4  0.6 vs 1.3  1.1; n ¼ 46;
P < .001) and in the UCEIS index (4.9  1.4 vs 2.3  2.3;
n ¼ 42; P < .001), between baseline and follow-up
colonoscopies (Supplementary Table 1).
Long-Term Outcomes
Among the overall population (n ¼ 104), after a
median follow-up of 23.6 months (IQR,12.9–57.9), 64%
(67/104) were in clinical remission at last follow-up.
Among these 104 patients, the cumulative probability
of sustained clinical remission was 87.6%  3.4% at 1
year, 74.7%  4.8% at 2 years, and 56.4%  6.2% at 5
years (Figure 2A). When considering only patients with
an initial response to anti-TNF therapy (n ¼ 80), the
cumulative probability of sustained clinical remission,
irrespective of the treatment given, was 90.5%  3.4% at
1 year, 77.9%  5.3% at 2 years, and 55.8%  7.4% at 5
years (Figure 2B). During follow-up, 9% (9/104) of pa-
tients were hospitalized for a flare of their UP and 4%
(4/104) underwent a coloproctectomy with ileal
pouch–anal anastomosis.
Among the 24 patients with primary nonresponse to
anti-TNF-a, 75% (18/24) of the patients were switch to 11 July 2019  9:13 pm  ce CJ
Figure 1. Efficacy of anti-TNF-a therapy in patients with
refractory ulcerative proctitis.



















































































547another anti-TNF-a agent and 46% (11/24) were even-
tually treated with vedolizumab with achievement of
clinical remission in 22% (4/18) and 82% (9/11) of the
cases, respectively. Among patients with an initial
response to anti-TNF-a, 19% (15/80) had a switch to
another anti-TNF-a and 11% (9/80) were eventually
treated with vedolizumab during follow-up withTable 2. Predictive Factors Associated With Primary Clinical Re




Sex, female vs male 1.471 0.679
Age at diagnosis, y 0.977 0.945
Smoking, yes vs no 0.458 0.080
Extraintestinal manifestations, yes vs no 0.316 0.123
Previous treatments, yes vs no
Local steroids 1.341 0.483
Systemic steroids 0.838 0.261
Local mesalamine 3.187 0.320




Mayo clinical subscore at baseline 1.016 0.821
Type of anti-TNF
SC vs IV 0.538 0.247
ADA vs IFX 0.633 0.278
GOL vs IFX 0.275 0.065
Duration of disease before anti-TNF, mo 1.000 0.997
Combination therapy with thiopurines, yes vs no 2.284 1.016
Ongoing drugs at anti-TNF start, yes vs no
Local steroids 0.115 0.024
Oral steroids 0.410 0.161
Local mesalamine 0.195 0.070
Oral mesalamine 0.722 0.245
ADA, adalimumab; anti-TNF, anti-tumor necrosis factor alpha monoclonal antibo
OR, odds ratio; SC, subcutaneous.
aVariables included in the multivariate analysis are sex, age at diagnosis, ext
concomitant thiopurines, ongoing treatment with topical mesalamine, ongoing tre
FLA 5.6.0 DTD  YJCGH56568_proofachievement of clinical remission in 53% (8/15) and
56% (5/9) of the cases, respectively.
At the end of the follow-up period, 61% (63/104) of
the patients were still on anti-TNF at last follow-up.
Among the 80 patients with a primary clinical response
to anti-TNF, 34% (27/80) stopped the first anti-TNF
agent for secondary loss of response, intolerance, or
surgery. In these patients (n ¼ 80), the cumulative
probability of first anti-TNF failure-free survival (no
withdrawal for secondary loss of response, intolerance,
and/or surgery) was 94.6%  2.6% at 6 months, 80.6%
 4.9% at 1 year, and 69.6%  5.9% at 2 years. Opti-
mization of anti-TNF therapy during follow-up was per-
formed in 43.7% of the patients (35/80). Failure of first
anti-TNF therapy defined as optimization, intolerance,
loss of response, or surgery was observed in 57.5% (46/
80) of the patients during follow-up.Safety of Anti–Tumor Necrosis Factor Therapy
There were missing data for 8 patients. Overall, 22%
(21/96) of the patients presented side effects after
starting anti-TNF therapy (Table 3). Three patients had
an infusion reaction leading to anti-TNF withdrawal; 5
patients had skin manifestations; 4 patients had anmission in Patients With Ulcerative Proctitis Treated With
Q7
iate analysis Multivariate analysisa


















0.541 .006 0.142 0.028 0.729 .019
1.044 .062
0.547 .002 0.211 0.069 0.648 .007
2.126 .555
dies; CI, confidence interval; GOL, golimumab; IFX, infliximab; IV, intravenous;
raintestinal manifestations, type of anti-TNF (subcutaneous vs intravenous),
atment with topical steroids, and ongoing treatment with oral steroids.



































Figure 2. Sustained clin-
ical remission during
follow-up in patients with
ulcerative proctitis treated
with anti-TNF. (A) Propor-
tion of patients with sus-
tained clinical remission
during follow-up in the
overall population (n ¼
104). (B) Proportion of pa-









































































































680infection; 1 patient presented alopecia; and 9 patients
had other side effects, such as arthralgia, headache,
abnormal liver enzymes, or weight gain.
Discussion
The management of refractory UP remains chal-
lenging in the era of biologics. These patients are
excluded from clinical trials on biologics and available
studies on the effectiveness of anti-TNF therapy in a real-
life setting are of small sample size.12 Because UP rep-
resents about one-third of all cases of UC, mesalamine
treatment is often insufficient in moderate to severe UC
and AZA has modest efficacy in this indication.13 Further
evidence regarding the potential of anti-TNF therapy in
treating these patients is eagerly awaited.
We first demonstrated that anti-TNF therapy, either
intravenously or subcutaneously, can induce a clinical
response in 77% of patients. These results are in line
with previous reports. Indeed, in a small retrospective
study on infliximab efficacy in patients with UP, 85% of
patients experienced clinical improvement.12 The Active
Ulcerative Colitis Trial (ACT; infliximab), ULTRA (adali-
mumab), and golimumab (PURSUIT) trials in patients
with pancolitis or left-sided colitis treated with inflix-
imab demonstrated short-term clinical response in about
63%–69% of patients whatever disease extension.14–16Table 3. Adverse Events in Patients With Ulcerative Proctitis









Abnormal liver enzymes 1
Weight gain 1
Muscle weakness 1
















696Moreover, in our study, clinical response was accompa-
nied by a significant drop in CRP levels. Similar changes
in CRP levels were reported in the previous retrospective
study on infliximab in patients with UP.12
Interestingly, no difference in clinical efficacy was
observed in our study between the 3 anti-TNF for pa-
tients with UP, because it has already been demonstrated
in population-based studies and network meta-analysis
for patients with UC.17 Importantly, UP patients treated
with anti-TNF in our study are truly refractory patients
with previous use of topical and oral mesalamine and
corticosteroids in a large majority of patients and pre-
vious failure of thiopurines in almost two-thirds of them.
Few studies have investigated other immunosup-
pressants to treat patient with UP. A recent retrospective
multicenter study assessing the efficacy of AZA in pa-
tients with refractory UP demonstrated that 71% (10/
14) of patients achieved short-term response and 21%
(3/14) steroid-free clinical remission. Also, in this study,
after a median follow-up of 46.2 (26.4–47.8) months,
only 5 patients receiving AZA out of 25 had treatment
success at the end of follow-up.13 Another multicenter,
randomized, double-blind, placebo-controlled, induction
trial compared the efficacy of a tacrolimus rectal oint-
ment (3 mL of tacrolimus at 0.5 mg/mL) administrated
twice a day for 8 weeks with rectal placebo in patients
(n ¼ 21) with refractory UP. In this study, 73% (8/11) of
the patients treated with tacrolimus achieved clinical
response. Clinical remission and mucosal healing were
achieved in 45% and 73% of the patients treated with
tacrolimus.9
It is well established that anti-TNF agents are able to
induce mucosal healing in patients with UC.18 Mucosal
healing is associated with better outcomes and is now a
therapeutic goal in our practice.18 In our study, we
observed mucosal healing (Mayo endoscopic subscore of
0 or 1) in 60% of the patients with available endoscopic
assessment. Moreover, there was a significant decrease
in the Mayo endoscopic subscore and UCEIS from base-
line to follow-up colonoscopies. ACT 1 and 2 studies
reported the same rate of mucosal healing at week 8 in
patents with UC treated with infliximab 5 mg/kg (62%
and 60%, respectively).14 The previous retrospective 11 July 2019  9:13 pm  ce CJ




















































































































812study on infliximab in 13 patients with UP reported
mucosal healing in only 2 of the 7 patients (28%) with
follow-up colonoscopies.12
Long-term follow-up is required to assess the sus-
tained efficacy of medical treatment in refractory UP. The
median follow-up in our study was 24 months. In pa-
tients with an initial response to anti-TNF, the proba-
bility of first anti-TNF failure-free survival at 2 years was
70%. More importantly, among the whole cohort, at the
end of the follow-up, 64% of the patients with refractory
UP were in clinical remission, with 61% still receiving an
anti-TNF agent. These data are in accordance with pre-
vious studies on the long-term outcome of patients
treated with infliximab for refractory UC, with a sus-
tained clinical response rate of 68% after a median
follow-up of 33 months.19
Previous studies have identified several clinical or
biologic factors influencing response to anti-TNF in UC,
such as severity of the disease, younger age, duration of
colitis, or extensive colitis.20 In our study, we found that
extraintestinal manifestations, ongoing topical steroids,
and mesalamine at baseline were significantly associated
with the absence of clinical remission in patients with
refractory UP. Another recent study also identified
extraintestinal manifestation as a risk factors for colec-
tomy in patients with UC on thiopurine treatment.21 In
our cohort combination therapy with thiopurines was
associated with clinical remission in univariate analysis
only, probably because of lack of statistical power.
Regarding ongoing treatment with topical mesalamine or
steroids, this may emphasize the fact that patients on
topical treatments at anti-TNF initiation might present
more refractory UP.
In the first retrospective study on UP, only 1 patient
relapsed after infliximab induction and underwent
proctocolectomy.12 In our cohort, 4% of patients un-
derwent proctocolectomy with ileoanal anastomosis.
This colectomy rate is lower than those reported in pa-
tients with left-sided or extensive UC (17%), as expected
given the limited disease extent.19 Very little is known
about the switch to another anti-TNF agent in patients
with refractory UP. Our cohort provides interesting data
showing that more than two-thirds of the patients with
anti-TNF primary nonresponse were switched to a sec-
ond anti-TNF during follow-up with achievement of
clinical remission in 22% of the cases. Moreover, half of
these patients eventually received vedolizumab during
follow-up with achievement of clinical remission in 82%
of patients.
The strengths of our study are the large number of
patients included, the nationwide character of the study,
and the duration of follow-up, which allowed us to look
at predictors of short and long-term efficacy. Moreover,
the availability of data on CRP, an objective biomarker of
intestinal inflammation, improved the strength of the
assessment of anti-TNF efficacy in these patients. Limi-
tations of our study are its retrospective character with
absence of comparator group and the absence ofFLA 5.6.0 DTD  YJCGH56568_proofsystematic assessment of mucosal healing. Moreover, we
were not able to collect data on fecal calprotectin, anti-
TNF trough level, or disease extension during follow-up.
In conclusion, our data support the use of anti-TNF
monoclonal antibodies in patients with refractory UP
with 50% of patients achieving clinical remission and
64% showing sustained clinical remission at the end of
follow-up. Moreover, our study also demonstrated that
anti-TNF agents are able to induce mucosal healing in
60% of patients with refractory UP. Regarding follow-up,
about half of the patients were still on anti-TNF therapy
at 2 years.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2019.05.060. 11References
1. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet
2012;380:1606–1619.
2. Meucci G, Vecchi M, Astegiano M, et al. The natural history of
ulcerative proctitis: a multicenter, retrospective study. Gruppo di
Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J
Gastroenterol 2000;95:469–473.
3. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal
classification of inflammatory bowel disease: controversies,
consensus, and implications. Gut 2006;55:749–753.
4. Gecse KB, Lakatos PL. Ulcerative proctitis: an update on the
pharmacotherapy and management. Expert Opin Pharmacother
2014;15:1565–1573.
5. Pineton de Chambrun G, Tassy B, Kollen L, et al. The treatment
of refractory ulcerative colitis. Best Pract Res Clin Gastroenterol
2018;32–33:49–57.
6. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled
trial of azathioprine and 5-aminosalicylic acid for treatment of
steroid dependent ulcerative colitis. Gut 2006;55:47–53.
7. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active
ulcerative colitis: a double-blind, randomized, Israeli multicenter
trial. Gastroenterology 1996;110:1416–1421.
8. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-
controlled trial of cyclosporine enemas for mildly to moderately
active left-sided ulcerative colitis. Gastroenterology 1994;
106:1429–1435.
9. Lawrance IC, Baird A, Lightower D, et al. Efficacy of rectal
tacrolimus for induction therapy in patients with resistant ul-
cerative proctitis. Clin Gastroenterol Hepatol 2017;
15:1248–1255.
10. Bageacu S, Coatmeur O, Lemaitre JP, et al. Appendicectomy as
a potential therapy for refractory ulcerative proctitis. Aliment
Pharmacol Ther 2011;34:257–258.
11. Molnar T, Farkas K, Nagy F, et al. Topically administered
infliximab can work in ulcerative proctitis despite the ineffec-
tiveness of intravenous induction therapy. Am J Gastroenterol
2009;104:1857–1858.
12. Bouguen G, Roblin X, Bourreille A, et al. Infliximab for refractory
ulcerative proctitis. Aliment Pharmacol Ther 2010;




























































































89913. Mallet AL, Bouguen G, Conroy G, et al. Azathioprine for re-
fractory ulcerative proctitis: a retrospective multicenter study.
Dig Liver Dis 2017;49:280–285.
14. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for in-
duction and maintenance therapy for ulcerative colitis. N Engl J
Med 2005;353:2462–2476.
15. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous
golimumab induces clinical response and remission in patients
with moderate-to-severe ulcerative colitis. Gastroenterology
2014;146:85–95; quiz e14–15.
16. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab
induces and maintains clinical remission in patients with
moderate-to-severe ulcerative colitis. Gastroenterology 2012;
142:257–265.
17. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with
network meta-analysis: the efficacy of anti-tumour necrosis
factor-alpha agents for the treatment of ulcerative colitis.
Aliment Pharmacol Ther 2014;39:660–671.
18. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting
Therapeutic Targets in Inflammatory Bowel Disease (STRIDE):
determining therapeutic goals for treat-to-target. Am J Gastro-
enterol 2015;110:1324–1338.
19. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after
infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;
2:219–225.
20. Zampeli E, Gizis M, Siakavellas SI, et al. Predictors of response
to anti-tumor necrosis factor therapy in ulcerative colitis. World J
Gastrointest Pathophysiol 2014;5:293–303.
21. Canas-Ventura A, Marquez L, Ricart E, et al. Risk of colectomy
in patients with ulcerative colitis under thiopurine treatment.
J Crohns Colitis 2014;8:1287–1293.FLA 5.6.0 DTD  YJCGH56568_proofReprint requests
Address requests for reprints to: G. Pineton de Chambrun, MD, PhD, Depart-
ment of Gastroenterology, Saint-Eloi Hospital, Montpellier University Hospital,
80 Av. Augustin Fliche, F-34295, Montpellier, France. e-mail:
g-pinetondechambrun@chu-montpellier.fr; fax: þ 33 4 67 33 76 94.
Acknowledgments
The authors thank the Association François Aupetit for its financial support.
The PROTECT-GETAID study group: Maria Nachury, Gilles Boschetti, Bernard
Flourié, Pauline Danion, Guillaume Savoye, Franck brazier, Julien Loreau,
Laurent Beaugerie, Harry Sokol, I. Nion-Larmurier, A. Bourrier, C. Landman, J.
Lefèvre, N. Chafai, Najima Bouta, and Natalie Funakoshi.
Conflicts of interest
These authors disclose the following: Guillaume Pineton de Chambrun has
received lecture fees from Pfizer, MSD, AbbVie, Takeda, and Ferring; and
consulting fees from Takeda, Tillots Pharma, and Janssen. Aurélien Amiot has
received consulting fees from Abbvie, Hospira, Takeda, Gilead, and Biocodex;
lecture fees and travel accommodations from Abbvie, Janssen, Biocodex,
Ferring, Takeda, and MSD; and advisory board fees from Gilead, Takeda, and
Abbvie. Guillaume Bouguen has received lecture fees from Abbvie, Ferring,
MSD, Takeda, and Pfizer; and consulting fees from Takeda and Janssen.
Stéphanie Viennot has received lecture fees from Pfizer, MSD, AbbVie, Takeda,
and Janssen; and consulting fees from Takeda and Janssen. Romain Altwegg
has received lecture fees from MSD, Abbvie, Pfizer, Takeda, and Janssen.
Michael Collins has received lecture fees from Abbvie, Takeda, and Celgene;
and consulting fees from AbbVie. Mathurin Fumery has received financial
support from Abbvie, MSD, Ferring, Boehringer, Pfizer, Takeda, and Tillots
Pharma. Florian Poullenot has received lecture fees from MSD, Abbvie, Pfizer,
Shire, Takeda, Janssen, and Ferring. Vered Abitbol has received fees from
Biogen, Abbvie, Takeda, Janssen, Amgen, Pfizer, Amgen, Vifor, Arkopharma,
and UCB. David Laharie has received board or lectures fees from Abbvie,
Celgene, Ferring, Janssen, MSD, Novartis, Pfizer, Roche, and Takeda. Philippe
Seksik has received consulting fees from Takeda, Abbvie, Merck-MSD, Bio-
codex, and Ferring Pharmaceuticals; grants from Biocodex; and sponsored
travel from Merck-MSD and Takeda. Stéphane Nancey has received lecture
fees from Pfizer, MSD, AbbVie, Takeda, Ferring, Janssen, Lilly, and Novartis;
and consulting fees from Abbvie, Takeda, Tillots Pharma, and Janssen. Pierre
Blanc has received lecture fees from Abbvie, Tillots Pharma, and Pfizer. Lau-
rent Peyrin-Biroulet has received fees from Abbvie, Janssen, MSD, Pfizer,





























Supplementary Table 1. Changes in Biologic and
Endoscopic Parameters With Anti-
TNF Therapy
Biologic parameter Baseline At 3 mo P value
Mean CRP level
(mg/L; n ¼ 49)
11.6  21.4 4.7  4.6 .028
Endoscopic parametersa Baseline Follow-up P value
Mayo endoscopic subscore
(from 0 to 3; n ¼ 46)
2.4  0.6 1.3  1.1 < .001
UCEIS index
(from 0 to 8; n ¼ 42)
4.9  1.4 2.3  2.3 < .001
Anti-TNF, anti-tumor necrosis factor alpha monoclonal antibodies; CRP,
C-reactive protein; IQR, interquartile range; UCEIS, Ulcerative Colitis Endo-
scopic Index of Severity.
aFollow-up colonoscopies were performed after a median delay from anti-TNF
initiation of 11.7 (IQR, 5.5–17.4) months.
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